Publications by authors named "Antonella Vasami"
Background: The Phase 1/2 Treat_CCM randomized controlled trial for people with familial cerebral cavernous malformations (FCCMs) confirmed the safety of propranolol and suggested beneficial effects on intracerebral hemorrhage or new focal neurological deficits, but the effects on patient-reported outcome measures have not been reported.
Methods: Participants completed self-reported questionnaires at baseline, 1 and 2 years. Depression was assessed with the Beck Depression Inventory-II (BDI-2); Anxiety with the State-Trait Anxiety Inventory X1 and X2 (STAI X-1 and STAI X-2); and Quality of Life with the Short Form 36 (SF-36), split into the physical and mental component scales (PCS and MCS).
Article Synopsis
- The study aims to determine if quantitative susceptibility mapping (QSM) can predict hemorrhagic signs in patients with cerebral cavernous malformations (CCMs) after one year.
- Researchers enrolled familial CCM patients and utilized 3-T MRI scans to measure QSMmax, finding higher susceptibility in hemorrhagic CCMs compared to non-hemorrhagic ones.
- The results indicated that QSMmax has good predictive accuracy for whether CCMs would still show hemorrhagic signs or remain stable after one year, highlighting its potential for follow-up assessments in larger studies.
Background: Cerebral cavernous malformations (CCMs) are vascular malformations characterized by clusters of enlarged leaky capillaries in the central nervous system. They may result in intracranial haemorrhage, epileptic seizure(s), or focal neurological deficits, and potentially lead to severe disability. Globally, CCMs represent the second most common intracranial vascular malformation in humans, and their familial form (FCCMs) accounts for one-fifth of cases.
View Article and Find Full Text PDF